Outlook Therapeutics announced it has bolstered its board of directors with the appointments of Prof. Dr. Gerd Auffarth and Julian Gangolli.
“We are incredibly pleased to add individuals of Dr. Auffarth’s and Mr. Gangolli’s caliber to the Outlook Therapeutics Board of Directors,” Lawrence A. Kenyon, President, CEO and CFO, Outlook Therapeutics, said in a company news release. “We believe that the significant R&D and clinical leadership and the knowledge of the ophthalmology space that Dr. Auffarth brings, as well as the deep commercialization expertise, including therapeutics for retinal diseases, that Mr. Gangolli adds will be invaluable as we advance our ongoing registration clinical trials for ONS-5010/Lytenava (bevacizumab-vikg) towards commercialization.”
Prof. Dr. Auffarth is an internationally recognized ophthalmologist in the area of research and development, as well as clinical care for patients. He currently serves as the Medical Director of Heidelberg University Eye Clinic. Prior to his appointment as Medical Director in 2011, he worked as a senior physician at the University Eye Clinic. He currently serves as the Director of the International Vision Correction Research Center (IVCRC) and the David J. Apple Laboratory for Ocular Pathology, which he has established in the University Eye Clinic and which are recognized worldwide in the field of implant and biomaterial research.
Mr. Gangolli is a leader in commercialization with a well-established track record and experience, having served as President of the North American Pharmaceutical division of Allergan for 11 years where he was a member of the Executive Committee of Allergan and was responsible for a 1,400-person commercial operation with sales exceeding $3.8 billion in 2014. Mr. Gangolli most recently served as President, North America of Greenwich Biosciences, a GW Pharmaceuticals, where he was responsible for building out the U.S. commercial infrastructure and spearheading the launch of its lead therapeutic product Epidiolex.
ONS-5010/Lytenava (bevacizumab-vikg) is an investigational ophthalmic formulation of bevacizumab under development to be administered as an intravitreal injection for the treatment of wet age-related macular degeneration (AMD) and other retinal diseases. ONS-5010 is currently being evaluated in two registration clinical trials for wet AMD (NORSE 1 and NORSE 2) and, if successful, is expected to be submitted to the FDA as a new biologics license application (BLA) for this ophthalmic indication. If approved, ONS-5010 will be the first and only FDA-approved ophthalmic formulation of bevacizumab to treat approved retinal diseases. The company currently intends to commercialize ONS-5010 in both vials and single-use pre-filled syringes.